Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Development of a recombinant respiratory syncytial virus phosphoprotein mimetic fused to a human carrier protein

FY 2015-16

Summary
Respiratory syncytial virus (RSV) is one of the leading causes of childhood hospitalizations, and infects almost all children at least once by the age of two. RSV can repeatedly infect people throughout their lives, therefore individuals with weak immune systems and the elderly population are at risk. Upon infection, young children may experience wheezing, bronchiolitis or pneumonia while symptoms in older children and adults consist of low grade fever and upper respiratory tract problems. Furthermore, RSV bears a significant health care burden. There are estimates of about 33.8 million annual causes of RSV in children globally, which results in at least 3.4 million hospitalizations and claiming approximately 66,000 to 199,000 lives. In the United States alone, the annual medical cost for RSV-related cases total to about $652 million USD. Yet, there is currently no available vaccine or cost-effective treatment for the prevention and treatment of RSV infection. Therefore, there is a pressing need for the development of novel anti-RSV drugs. The laboratory I work in has developed a novel anti-RSV drug, which can reduce the number of RSV-infected cells without showing any significant short and long-term toxic effects. However, it is currently not compatible for human use. The goal of my project is to find a solution to this problem and to test the new drug's effectiveness in reducing RSV infection.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
350082
Name
Chiang Christopher K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a recombinant respiratory syncytial virus phosphoprotein mimetic fused to a human carrier protein
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiviral; Cell Viability; Darpin; Infection; Peptide Mimetic; Phosphoprotein; Respiratory Syncytial Virus; Toxicity; Viral Inhibition
Abstract
Respiratory syncytial virus (RSV) is one of the leading causes of childhood hospitalizations, and infects almost all children at least once by the age of two. RSV can repeatedly infect people throughout their lives, therefore individuals with weak immune systems and the elderly population are at risk. Upon infection, young children may experience wheezing, bronchiolitis or pneumonia while symptoms in older children and adults consist of low grade fever and upper respiratory tract problems. Furthermore, RSV bears a significant health care burden. There are estimates of about 33.8 million annual causes of RSV in children globally, which results in at least 3.4 million hospitalizations and claiming approximately 66,000 to 199,000 lives. In the United States alone, the annual medical cost for RSV-related cases total to about $652 million USD. Yet, there is currently no available vaccine or cost-effective treatment for the prevention and treatment of RSV infection. Therefore, there is a pressing need for the development of novel anti-RSV drugs. The laboratory I work in has developed a novel anti-RSV drug, which can reduce the number of RSV-infected cells without showing any significant short and long-term toxic effects. However, it is currently not compatible for human use. The goal of my project is to find a solution to this problem and to test the new drug's effectiveness in reducing RSV infection.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chiang, Christopher K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~